Recent Updates
Recently added Catalysts
JANX Positive Sentiment

Janux Therapeutics Announces Positive Initial Phase 1 Data for JANX011 in Healthy Volunteers, Supporting Planned Development in Patients with Autoimmune Disease

Monday, November 9, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Janux Therapeutics reported positive initial results from its Phase 1 study of JANX011 in healthy volunteers. This data supports the company's plans to develop the drug for autoimmune diseases. JANX011 is the first candidate from Janux's Adaptive Immune Response Modulator platform to enter clinical trials.

Market Sentiment Analysis

POSITIVE FACTORS

  • Initial Phase 1 data shows promising results.
  • Supports development in autoimmune diseases.
  • First program from Janux's ARM platform.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+10%
120-day peak, hindsight
Typical move
7.9%
average across 5 past catalysts
Cash runway
~113 mo
Minimal dilution risk
Lead asset
JANX007
Phase 1 · Prostate Cancer

Full Press Release Details

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced initial clinical results from the Phase 1 study of JANX011 in healthy volunteers and outlined its planned clinical development strategy in autoimmune diseases. JANX011 is the first program from Janux’s proprietary Adaptive Immune Response Modulator (ARM) platform to enter clinical development. The ARM platfo

Frequently Asked Questions

What are the initial results for JANX011?

The initial Phase 1 results for JANX011 are positive.

What is JANX011 targeting?

JANX011 is being developed for autoimmune diseases.

What platform does JANX011 come from?

JANX011 is from Janux's Adaptive Immune Response Modulator platform.

Who conducted the Phase 1 study?

Janux Therapeutics conducted the Phase 1 study.

ShareAdd on Google
Tags: JANX Janux Therapeutics JANX011 Phase 1 autoimmune diseases clinical trials
Last updated: Nov 9, 2026

Biotech snapshot

Cash runway
$946M liquidity · $8M/mo burn
~113 mo
Minimal dilution risk
Lead asset
JANX007Phase 1
Prostate Cancer →

Catalyst track record

+10%
best trade around JANX's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for JANX.

See every catalyst's timing & PoA →